HER2‐positive breast cancer brain metastasis: A new and exciting landscape
Abstract Background Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous system (CNS) metastases. Systemic anti‐HER2 th...
Main Authors: | Alexandra S. Zimmer, Amanda E. D. Van Swearingen, Carey K. Anders |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-04-01
|
Series: | Cancer Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/cnr2.1274 |
Similar Items
-
Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature
by: Axel de Bernardi, et al.
Published: (2024-01-01) -
Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
by: Inge M. Werter, et al.
Published: (2022-11-01) -
Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
by: Alejandro Garcia-Alvarez, et al.
Published: (2021-06-01) -
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
by: Zaid Sirhan, et al.
Published: (2022-07-01) -
Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
by: Peter A. Kaufman, et al.
Published: (2023-10-01)